Short interest for MediWound gives investors a sense of the degree to which investors are betting on the decline of MediWound's stock. Short interest data is updated every two weeks.

MediWound Stock (NASDAQ:MDWD), Short Interest Report

MediWound

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Equities

News

Contracts

Small Cap

Markets

General

MDWD

VCEL

Biopharmaceutical company MediWound Ltd (NASDAQ: MDWD) reported that the U.S.

Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development

Price Target

Pre-Market Outlook

Analyst Ratings

Trading Ideas

HAYW

INTU

MSFT

NTRS

SBUX


	UBS cut  Microsoft Corporation  (NASDAQ: MSFT) price  target from $300 to $250. UBS analyst Karl Keirstead downgraded the stock from Buy to Neutral. Microsoft shares fell 2% to $234.73 in pre-market trading.


Starbucks To Rally 11%? Here Are 10 Other Analyst Forecasts For Wednesday

Biotech

Health Care

FDA Approves MediWound&#39;s NexoBrid For Burn Treatment

MediWound Ltd

Oral presentations include additional comparative data between EscharEx&#xAE; and SANTYL&#xAE;, and new analyses show strong correlation between wound bed preparation and wound healing &nbsp;
Analyses validate the planned design and endpoints of the upcoming Phase III study
YAVNE, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>), the global leader in next-generation enzymatic therapeutics for tissue repair, announced today that recent clinical data from EscharEx&#xAE; Phase II studies will be presented throughout May 2024 at the largest, most prestigious annual meetings in the field of chronic wound care: the European Wound Management Association (EWMA), the Wound Healing Society (WHS), and the Symposium on Advanced Wound Care (SAWC).
The oral presentations on EscharEx will include:
<ul>
<li>Comparative data of EscharEx vs. SANTYL&#xAE; that demonstrate EscharEx's superiority over the current leading enzymatic debridement agent</li>
<li>New analyses from the ChronEx phase II study, showing high correlation between wound bed preparation and wound healing</li>
</ul>
These data indicate that EscharEx could substantially improve wound care for patients with debilitating chronic wounds, providing significant benefits over the current standard of care. Additionally, the findings support the design and endpoints of the upcoming Phase III study, which is expected to begin in the second half of 2024.
"We are delighted to present the results of additional analyses from EscharEx Phase II studies in chronic hard-to-heal wounds, including the positive comparative data with SANTYL&#xAE;, the current dominant standard of care for enzymatic debridement," said Dr. Robert J. Snyder, Chief Medical Officer of MediWound. "With its robust efficacy, favorable safety profile, and multimodal mechanistic effects demonstrated in these Phase II studies, we believe that EscharEx can significantly advance wound care and has the potential to become a major player in the global wound care market."
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2">2024 European Wound Management Association (EWMA), London, United Kingdom</td>
</tr>
<tr>
<td>Time:</td>
<td>May 1, at 11:45am</td>
</tr>
<tr>
<td>Title:</td>
<td>Comparison of bromelain-based enzymatic debridement to collagenase ointment</td>
</tr>
<tr>
<td>Presenter:</td>
<td>Cyaandi R. Dove, DPM</td>
</tr>
<tr>
<td>Time:</td>
<td>May 3, at 8:30am</td>
</tr>
<tr>
<td>Title:</td>
<td>VLU wound bed preparation is highly correlated with wound closure</td>
</tr>
<tr>
<td>Presenter:</td>
<td>Robert J. Snyder, DPM, MSc, MBA</td>
</tr>
<tr>
<td colspan="2">2024 Wound Healing Society Conference (WHS), Orlando, Florida</td>
</tr>
<tr>
<td>Time:</td>
<td>May 16, at 10:30am</td>
</tr>
<tr>
<td>Title:</td>
<td>Comparison of bromelain-based enzymatic debridement to collagenase SANTYL&#xAE; ointment</td>
</tr>
<tr>
<td>Presenter:</td>
<td>Cyaandi R. Dove, DPM</td>
</tr>
<tr>
<td>Time:</td>
<td>May 16, at 10:30am</td>
</tr>
<tr>
<td>Title:</td>
<td>VLU wound bed preparation is highly correlated with wound closure&nbsp;</td>
</tr>
<tr>
<td>Presenter:</td>
<td>Marissa Carter, MA, PhD</td>
</tr>
<tr>
<td colspan="2">2024 Symposium on Advanced Wound Care (SAWC), Orlando, Florida</td>
</tr>
<tr>
<td>Time:</td>
<td>May 17, at 7:30am</td>
</tr>
<tr>
<td>Location:</td>
<td>SAWC Innovation Theater</td>
</tr>
<tr>
<td>Title:</td>
<td>EscharEx, an innovative multimodal enzymatic debridement agent for the treatment of chronic wounds</td>
</tr>
<tr>
<td>Presenters:</td>
<td>Vickie R. Driver, DPM, MS, FACFAS, John C. Lantis, MD, Cyaandi R. Dove, DPM, and Robert J. Snyder, DPM, will discuss the importance of wound bed preparation in wound healing, EscharEx's mechanism of action, results from the ChronEx Phase II study including case studies showcasing the treatment experience, and the design of the upcoming Phase III study in venous leg ulcers (VLU)</td>
</tr>
</tbody>
</table>
</figure>
About EscharEx
EscharEx&#xAE; is a bioactive, multimodal debridement therapy for the treatment of chronic and other hard-to-heal wounds, currently in advanced stages of clinical development. It is a concentrate of proteolytic enzymes enriched with bromelain for topical, easy to use daily applications. In several Phase II trials, EscharEx was shown to be safe and well-tolerated. It demonstrated efficacy in debridement, the promotion of granulation tissue, and the reduction of bioburden and biofilm in various hard-to-heal wounds. EscharEx's mechanism of action is mediated by a mixture of multiple proteolytic enzymes that remove non-viable tissue preparing the wound bed for healing. A Phase III study in patients with VLU, is planned to start in the second half of 2024.

MediWound To Present New Data From EscharEx Phase II Studies At 3 Wound Care Conferences

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and maintains $28 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $28 Price Target

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 83.9 percent increase over losses of $(1.18) per share from the same period last year. The company reported quarterly sales of $5.34 million which beat the analyst consensus estimate of $5.32 million by 0.34 percent. This is a 54.05 percent decrease over sales of $11.62 million the same period last year.

Earnings

MediWound Q4 EPS $(0.19) Beats $(0.23) Estimate, Sales $5.34M Beat $5.32M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Creative Realities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREX#NASDAQ">CREX</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
&bull; InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) is projected to report quarterly loss at $0.20 per share on revenue of $1.42 million.
&bull; Fennec Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FENC#NASDAQ">FENC</a>) is likely to report quarterly loss at $0.02 per share on revenue of $8.67 million.
&bull; Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $218.97 million.
&bull; VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) is expected to report quarterly loss at $0.03 per share on revenue of $8.95 million.
&bull; Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) is expected to report quarterly earnings at $2.29 per share on revenue of $1.79 billion.
&bull; Exscientia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAI#NASDAQ">EXAI</a>) is expected to report quarterly loss at $0.35 per share on revenue of $17.05 million.
&bull; Direxion Daily CSI China Internet Index Bull 2X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWEB#NYSE">CWEB</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $32.93 million.
&bull; Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) is likely to report quarterly earnings at $0.88 per share on revenue of $720.40 million.
&bull; Commercial Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) is projected to report quarterly earnings at $0.73 per share on revenue of $1.80 billion.
&bull; Titan Machinery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) is projected to report quarterly earnings at $1.02 per share on revenue of $724.20 million.
&bull; Designer Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) is expected to report quarterly loss at $0.47 per share on revenue of $747.35 million.
&bull; Baozun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZUN#NASDAQ">BZUN</a>) is expected to report quarterly earnings at $0.16 per share on revenue of $382.28 million.
&bull; LiqTech Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIQT#NASDAQ">LIQT</a>) is likely to report quarterly loss at $0.24 per share on revenue of $5.40 million.
&bull; MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is estimated to report quarterly loss at $0.23 per share on revenue of $5.32 million.
&bull; Yunji (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) is projected to report earnings for its fourth quarter.
&bull; Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) is estimated to report earnings for its Fiscal Year 2023.
&bull; Mineralys Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) is estimated to report earnings for its fourth quarter.
&bull; FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) is likely to report quarterly earnings at $3.88 per share on revenue of $546.75 million.
&bull; Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) is expected to report quarterly earnings at $2.64 per share on revenue of $3.03 billion.
&bull; Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) is likely to report quarterly earnings at $2.66 per share on revenue of $15.83 billion.
&bull; X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) is expected to report earnings for its fourth quarter.
&bull; Lufax Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LU#NYSE">LU</a>) is likely to report quarterly loss at $0.02 per share on revenue of $1.05 billion.
&bull; Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) is estimated to report quarterly loss at $0.36 per share on revenue of $22.20 million.
&bull; Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) is projected to report quarterly loss at $0.51 per share on revenue of $8.20 million.
&bull; Yiren Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) is likely to report earnings for its fourth quarter.
&bull; Kirkland&#39;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIRK#NASDAQ">KIRK</a>) is expected to report quarterly earnings at $0.42 per share on revenue of $167.22 million.
&bull; Gambling.com Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $27.69 million.
&bull; MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) is likely to report earnings for its fourth quarter.
&bull; Nano Dimension (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNDM#NASDAQ">NNDM</a>) is likely to report earnings for its fourth quarter.
&bull; Shoe Carnival (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) is likely to report quarterly earnings at $0.59 per share on revenue of $280.27 million.
&bull; Destination XL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) is projected to report quarterly earnings at $0.06 per share on revenue of $138.29 million.
&bull; CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) is estimated to report quarterly loss at $0.34 per share on revenue of $30.88 million.
&bull; Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) is estimated to report quarterly loss at $0.18 per share on revenue of $14.85 million.
&bull; SNDL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) is likely to report earnings for its fourth quarter.
&bull; 111 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YI#NASDAQ">YI</a>) is likely to report earnings for its fourth quarter.
&bull; Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) is projected to report quarterly loss at $0.07 per share on revenue of $22.63 million.
&bull; CENTRAL &amp; EASTERN EUROPE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEE#NYSE">CEE</a>) is expected to report earnings for its Fiscal Year 2023.
<h3>Companies Reporting After The Bell</h3>
&bull; Largo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGO#NASDAQ">LGO</a>) is estimated to report quarterly loss at $0.05 per share on revenue of $47.10 million.
&bull; Xos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) is projected to report quarterly loss at $1.92 per share on revenue of $17.05 million.
&bull; Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) is projected to report quarterly earnings at $5.00 per share on revenue of $3.19 billion.
&bull; Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) is estimated to report quarterly loss at $0.99 per share on revenue of $49.15 million.
&bull; Vitru (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRU#NASDAQ">VTRU</a>) is projected to report earnings for its fourth quarter.
&bull; Scholastic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>) is projected to report quarterly loss at $0.80 per share on revenue of $329.21 million.
&bull; Worthington Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) is estimated to report quarterly earnings at $0.84 per share on revenue of $700.50 million.
&bull; Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $15.06 million.
&bull; Asensus Surgical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASXC#AMEX">ASXC</a>) is likely to report quarterly loss at $0.08 per share on revenue of $5.30 million.
&bull; Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $13.55 million.
&bull; Biolase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOL#NASDAQ">BIOL</a>) is projected to report quarterly loss at $2.55 per share on revenue of $13.55 million.
&bull; HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) is projected to report quarterly loss at $0.06 per share on revenue of $8.60 million.
&bull; Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) is likely to report quarterly earnings at $0.74 per share on revenue of $12.28 billion.
&bull; FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) is likely to report quarterly earnings at $3.53 per share on revenue of $22.05 billion.
&bull; Intellicheck (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDN#NASDAQ">IDN</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $5.31 million.
&bull; Abacus Life (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) is estimated to report earnings for its fourth quarter.
&bull; AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) is estimated to report quarterly earnings at $0.84 per share on revenue of $567.63 million.
&bull; Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) is expected to report quarterly loss at $0.11 per share on revenue of $2.70 million.
&bull; CaliberCos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWD#NASDAQ">CWD</a>) is likely to report quarterly loss at $0.17 per share on revenue of $4.25 million.
&bull; Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) is estimated to report quarterly loss at $0.18 per share on revenue of $3.71 million.
&bull; Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) is estimated to report quarterly loss at $1.43 per share on revenue of $380 thousand.
&bull; Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $65.95 million.
&bull; TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) is expected to report quarterly loss at $0.43 per share on revenue of $16.39 million.
&bull; One Stop Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSS#NASDAQ">OSS</a>) is projected to report quarterly loss at $0.04 per share on revenue of $13.01 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ALUR

AMPX

APYX

ASXC

BIOL

BZUN

CBUS

CCLD

CREX

CUTR

CWEB

DERM

DRCT

DXLG

EXAI

FENC

GAMB

HYPR

IFRX

INKT

IPHA

KIRK

LIQT

LULU

LUNR

MLYS

NNDM

RMTI

SCHL

SCVL

SNDL

TELA

TITN

VRME

VTRU

WELL

XFOR

Earnings Scheduled For March 21, 2024

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-21. Here's what investors need to know before the announcement.
Analysts estimate that MediWound will report an earnings per share (EPS) of $-0.23. 
MediWound bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.20, which was followed by a 3.57% increase in the share price the next day.
Here's a look at MediWound's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.44</td>
<td>-0.41</td>
<td>-0.30</td>
<td>-0.59</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.24</td>
<td>0.10</td>
<td>-0.44</td>
<td>-1.18</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>-2.0%</td>
<td>2.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1710954058_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of MediWound were trading at $15.73 as of March 19. Over the last 52-week period, shares are up 32.2%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/MDWD/earnings">To track all earnings releases for MediWound visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: MediWound's Earnings

Results from the previously disclosed Phase II study (ChronEx) which evaluated the safety and efficacy of EscharEx, demonstrated the superiority of EscahrEx vs. a gel vehicle (placebo) and non-surgical standard of care (NSSOC), in achieving complete debridement of non-viable tissue and promotion of granulation tissue (healthy, highly vascularized tissue). The secondary analyses announced today assessed the incidence and time to complete debridement, complete granulation, and wound closure in patients treated with EscharEx (n=46) compared to a sub-group of patients who were treated with SANTYL (n=8).

MediWound Announced The Results Of Head-To-Head Comparison Analyses Of EscharEx To Collagenase SANTYL Ointment, Approved By The FDA For Debriding Chronic Dermal Ulcers

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and raises the price target from $26 to $28.

HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $28

MediWound Says FDA Accepted For Review The Supplement To The NexoBrid BLA To Include Pediatric Patients With Severe Thermal Burns

Biopharmaceutical company&nbsp;MediWound Ltd&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdwd#NASDAQ">MDWD</a>) reported that the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), has awarded the company an&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/12/g36409105/mediwound-secures-additional-u-s-department-of-defense-funding-to-advance-nexobrid-development-for" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">additional $6.7 million in non-dilutive funding</a>.
The fund is to develop NexoBrid as a non-surgical solution for field-care burn treatment for the U.S. Army.
The $14.4 million project budget is expected to boost the development and production of a new, temperature-stable formulation of NexoBrid.
&quot;The additional funding will enhance our CMC activities, expedite preclinical development, and facilitate the establishment of a GMP compliant aseptic production line for the temperature-stable formulation of NexoBrid,&quot; said CEO Ofer Gonen.
Vericel Corporation&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vcel#NASDAQ">VCEL</a>) holds an exclusive license for the commercial and development rights to NexoBrid in North America, under an agreement with MediWound.
The MTEC Research Project Award was granted by the DoD&#39;s U.S. Army Medical Research and Development Command (USAMRDC) and funded by the Defense Health Agency through MTEC, a biomedical technology consortium.
Price Action: MDWD shares are trading higher by 2.02% at $10.41 on the last check Thursday.
Photo via Company

MediWound Disclosed That The US Department Of Defense Awarded An Additional $6.7M In Non-dilutive Funding To Develop NexoBrid As A Non-surgical Solution For Field-care Burn Treatment For The US Arm

MediWound Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the publication of a peer-reviewed paper, titled "An Open-label, Proof of Concept Study, Assessing the Effects of Bromelain-Based Enzymatic Debridement on Biofilm&nbsp;and&nbsp;Microbial&nbsp;Loads&nbsp;in Patients with&nbsp;Venous Leg and&nbsp;Diabetic Foot&nbsp;Ulcers" in the December 2023 issue of <a href="https://www.globenewswire.com/Tracker?data=uSDcAZeI-Ox8PbYX2S5DqnhXRxKkxiMsQvY7dL8obEmYCjTvi6COnZESxOH_664Q6pb3VtZ8sAYSQFFyS3Ybpsk9vvLIqoqyo08IToIh1NFnLJWiKWOF8RYANAMIBrC_H89bIkmgu8TLK-nW2269HYdMX0UgQbyxEbDBrNlKc-KIZ1JkaCSkosoiTYNXXAcpyYzeAXXlgqYaXtf8WRj6d2ckfjkCHi6PS2u8-3_erd8=">WOUNDS Journal</a>. &nbsp;
The paper highlights results from a Phase II study, which explored the mechanism of action of EscharEx, a novel bromelain based enzymatic debridement agent, in 12 patients with either venous leg ulcers (VLUs) or diabetic foot ulcers (DFUs). Results show that EscharEx not only effectively debrides wounds, but also reduces biofilm and bacterial load in both VLUs and DFUs.
Key findings:
<ul>
<li>70% of the patients (7/10) that completed the study achieved complete debridement within a median time of 5.5 days. An average reduction of 35% in wound size was achieved by the end of the 2-week follow-up period.</li>
<li>In all (100%) six patients positive for biofilm at baseline, EscharEx reduced the biofilm to a single individual or undetectable microorganisms, by the end of treatment based on tissue biopsies.</li>
<li>Bacterial load was reduced by 64% following treatment with EscharEx based on a fluorescence imaging device.</li>
<li>EscharEx was shown to be safe and well tolerated.</li>
</ul>
Dr. Rob Snyder, Chief Medical Officer of MediWound, emphasized the significance of these findings, stating, "Preparing a wound for closure in a timely fashion is critical to help reduce the burden associated with chronic wounds, including the potential downstream consequences of amputation and mortality. Together with the outcomes of our previous Phase II study results, this study furthers the understanding of the effects of EscharEx. It demonstrates its effectiveness not only in enzymatic debridement and promotion of granulation tissue, but potentially also in reducing biofilm and bacterial load. This dual mechanism of action may not only shift the disrupted healing process in chronic wounds towards a normal healing process, but may also prevent severe complications. We look forward to the initiation of the Phase III pivotal study in the second half of 2024 and, ultimately bringing this important non-surgical treatment to the millions of patients affected by chronic wounds."

MediWound Announces Peer-Reviewed Publication Of EscharEx Mechanism Of Action Study Assessing Its Effects On Biofilm And Microbial Loads

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and maintains $26 price target.

HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $26 Price Target

<h3>Companies Reporting Before The Bell</h3>
&bull; Golden Ocean Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOGL#NASDAQ">GOGL</a>) is likely to report quarterly earnings at $0.11 per share on revenue of $149.42 million.
&bull; Singing Machine Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MICS#NASDAQ">MICS</a>) is likely to report earnings for its second quarter.
&bull; Yiren Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) is projected to report earnings for its third quarter.
&bull; Arqit Quantum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) is expected to report earnings for its Fiscal Year 2023.
&bull; Northern Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTIC#NASDAQ">NTIC</a>) is estimated to report quarterly earnings at $0.18 per share on revenue of $21.40 million.
&bull; MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is likely to report quarterly loss at $0.44 per share on revenue of $4.74 million.
&bull; Dycom Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DY#NYSE">DY</a>) is projected to report earnings for its third quarter.
&bull; Yatsen Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YSG#NYSE">YSG</a>) is expected to report earnings for its third quarter.
&bull; Tuniu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOUR#NASDAQ">TOUR</a>) is projected to report earnings for its third quarter.
&bull; Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) is likely to report earnings for its third quarter.
&bull; Caleres (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAL#NYSE">CAL</a>) is expected to report earnings for its third quarter.
&bull; Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNP#NYSE">TNP</a>) is expected to report earnings for its third quarter.
&bull; Kingsoft Cloud Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) is likely to report earnings for its third quarter.
&bull; Jacobs Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) is estimated to report quarterly earnings at $1.89 per share on revenue of $4.16 billion.
&bull; American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) is projected to report earnings for its third quarter.
&bull; Dick&#39;s Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) is estimated to report earnings for its third quarter.
&bull; Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) is expected to report earnings for its third quarter.
&bull; Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) is expected to report quarterly loss at $0.13 per share on revenue of $5.07 million.
&bull; Kohl&#39;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) is estimated to report quarterly earnings at $0.33 per share on revenue of $4.11 billion.
&bull; Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) is likely to report earnings for its third quarter.
&bull; New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $760.00 million.
&bull; Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) is expected to report quarterly earnings at $2.00 per share on revenue of $2.70 billion.
&bull; Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is projected to report quarterly earnings at $1.19 per share on revenue of $9.91 billion.
&bull; iQIYI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $1.10 billion.
&bull; Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) is projected to report quarterly earnings at $1.18 per share on revenue of $7.92 billion.
&bull; Hibbett (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIBB#NASDAQ">HIBB</a>) is estimated to report earnings for its third quarter.
&bull; Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) is likely to report earnings for its fourth quarter.
&bull; Golar LNG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLNG#NASDAQ">GLNG</a>) is estimated to report quarterly earnings at $0.44 per share on revenue of $73.81 million.
&bull; Lowe&#39;s Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) is expected to report earnings for its third quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) is projected to report earnings for its third quarter.
&bull; Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $40.17 million.
&bull; TDCX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDCX#NYSE">TDCX</a>) is projected to report earnings for its third quarter.
&bull; Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) is projected to report earnings for its third quarter.
&bull; Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) is likely to report earnings for its third quarter.
&bull; Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is likely to report earnings for its third quarter.
&bull; DLocal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) is likely to report quarterly earnings at $0.15 per share on revenue of $168.51 million.
&bull; HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) is likely to report earnings for its fourth quarter.
&bull; NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is expected to report quarterly earnings at $3.16 per share on revenue of $15.19 billion.
&bull; Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) is estimated to report quarterly earnings at $1.15 per share on revenue of $372.44 million.
&bull; Banco BBVA Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAR#NYSE">BBAR</a>) is estimated to report earnings for its third quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ADSK

ARQQ

BBAR

BIDU

BURL

CRGO

EMBC

GLNG

GOGL

HIBB

JACK

MICS

NTIC

NVDA

TDCX

TOUR

Earnings Scheduled For November 21, 2023

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported its Q3 earnings results on Tuesday, November 21, 2023 at 07:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
MediWound beat estimated earnings by 45.45%, reporting an EPS of $-0.24 versus an estimate of $-0.44.
Revenue was down $1.03 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.51 which was followed by a 1.54% drop in the share price the next day.
Here's a look at MediWound's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.41</td>
<td>-0.30</td>
<td>-0.59</td>
<td>-0.56</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.10</td>
<td>-0.44</td>
<td>-1.18</td>
<td>-0.91</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>4.19M</td>
<td>5.15M</td>
<td>6.60M</td>
<td>4.82M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>4.77M</td>
<td>3.80M</td>
<td>11.62M</td>
<td>5.80M</td>
</tr>
</tbody>
</table>

To track all earnings releases for MediWound <a href="https://www.benzinga.com/quote/MDWD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: MediWound Q3 Earnings

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.44) by 45.45 percent. This is a 72.73 percent increase over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $4.78 million which beat the analyst consensus estimate of $4.74 million by 0.76 percent. This is a 17.70 percent decrease over sales of $5.80 million the same period last year.

MediWound Q3 EPS $(0.24) Beats $(0.44) Estimate, Sales $4.78M Beat $4.74M Estimate

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is set to give its latest quarterly earnings report on Tuesday, 2023-11-21. Here's what investors need to know before the announcement.
Analysts estimate that MediWound will report an earnings per share (EPS) of $-0.44. 
MediWound bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.51, which was followed by a 1.54% drop in the share price the next day.
Here's a look at MediWound's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.41</td>
<td>-0.30</td>
<td>-0.59</td>
<td>-0.56</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.10</td>
<td>-0.44</td>
<td>-1.18</td>
<td>-0.91</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.54%</td>
<td>1.56%</td>
<td>2.63%</td>
<td>-10.78%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1700492461_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of MediWound were trading at $8.33 as of November 17. Over the last 52-week period, shares are down 22.68%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/MDWD/earnings">To track all earnings releases for MediWound visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For MediWound

MediWound Announces A Collaboration With PolyMedics Innovations (PMI) for NexoBrid Distribution In Europe

MediWound Addresses Emergency Demand For NexoBrid To Treat The Mass Of Burn Casualties, Inflicted By The War In Israel

HC Wainwright &amp; Co. has decided to maintain its Buy rating of MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) and raise its price target from $23.00 to $26.00.
Shares of MediWound are trading up 4.97% over the last 24 hours, at $9.50 per share.
A move to $26.00 would account for a 173.68% increase from the current share price.
<h3>About MediWound</h3>
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from the United States.
<h3>About Analyst Ratings</h3>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HC Wainwright & Co. Maintains Buy Rating for MediWound: Here's What You Need To Know

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and raises the price target from $23 to $26.

HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $26

MediWound reports mixed Q4 results; initiates FY24 outlook

Mediwound (MDWD) has released an update. MediWound Ltd. reported a strong 2023 with $19 million in revenue and significant advancements for its enz...

MediWound Boasts Robust 2023 Financials and Growth

MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript

MediWound Ltd. 2023 Q4 - Results - Earnings Call Presentation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MediWound (NASDAQ:<a href="https://investorplace.com/stock-quotes/mdwd-stock-quote/">MDWD</a>) just reported results for the fourth quarter of 2023.<ul><li>MediWound reported earnings per share of -19 cents. This was above the analyst estimate for EPS of -23 cents.</li><li>The company reported revenue of $5.34 million.</li><li>This was 0.34% better than the analyst estimate for revenue of $5.32 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/mdwd-stock-earnings-mediwound-for-q4-of-2023/">MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023

Josh Jennings, an analyst from TD Cowen, reiterated the Buy rating on Mediwound (MDWD – Research Report). The associated price target is $25.00. Jo...

Mediwound Poised for Growth: A Strong Buy Recommendation Amidst Promising Prospects and Strategic Expansion

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mediwound (MDWD – Research Report), Medtronic (MDT –...

Analysts Offer Insights on Healthcare Companies: Mediwound (MDWD), Medtronic (MDT) and Eledon Pharmaceuticals (ELDN)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eledon Pharmaceuticals (ELDN – Research Report), Med...

Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Medtronic (MDT) and Mediwound (MDWD)

Mediwound Ltd (MDWD) is around the top of the Biotechnology industry according to InvestorsObserver. MDWD received an overall rating of 86, which means that it scores higher than 86 percent of all stocks. Mediwound Ltd also achieved a score of 97 in the Biotechnology industry, putting it above 97 percent of Biotechnology s

Should You Hold Mediwound Ltd (MDWD) in Biotechnology Industry?

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mediwound (MDWD – Research Report) and Ironwood Phar...

Analysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), Ironwood Pharma (IRWD)

ELDN

IRWD

Press Releases

MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

Financing

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

MediWound to Participate in Two Upcoming Investor Conferences

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

Opinion

Thinking about buying stock in Mediwound, AeroVironment, Airship AI, Lyell Immunopharma, or Sunshine Biopharma?

MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences